EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor

Munich, 29 January 2024 – Today, the management board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ("Company" or "Formycon"), with the consent of the Company's supervisory board, resolved to increase the Company's share capital against cash contributions by issuing new no par-value bearer shares of the Company ("New Shares"), partially utilizing the authorized capital and excluding the shareholders' subscription rights ("Capital Increase"). Through the Capital Increase, the Company's share capital will be increased from currently EUR 16,053,025.00 by EUR 1,603,877.00 to EUR 17,656,902.00 by issuing 1,603,877 new no par-value bearer shares with a notional value in the Company’s share capital of EUR 1.00 per share. The gross proceeds from the Capital Increase amount to approximately EUR 82.84 million.

All New Shares were subscribed by Gedeon Richter Plc. (“Gedeon Richter"), a Hungary based major multinational specialty pharmaceutical company with core competences in research and manufacturing, in a private placement under exclusion of the shareholders' subscription rights at an issue price of EUR 51.65 per New Share representing the mean average value between today’s XETRA closing price and the volume-weighted average price of the Company's shares over the last thirty trading days. Following the Capital Increase, Gedeon Richter will hold about 9.08% of the Company's share capital and be subject to a customary lock-up obligation of 180 days.

The net proceeds from the Capital Increase will primarily be used for the further development of Formycon‘s existing biosimilar pipeline, especially its biosimilar candidates FYB206, FYB208 and FYB209. In addition, the start of FYB210, a new biosimilar candidate is planned for second half of this year.

Following the registration of the consummation of the Capital Increase with the commercial register, the New Shares will be included to trading on the “Scale” segment of the Regulated Unofficial Market of the Frankfurt Stock Exchange.

Important Notice:

This announcement and the information contained herein are for informational purposes only and do not constitute a prospectus or an offer to sell or a solicitation of an offer to buy any securities of the Company in the United States of America (including its territories and possessions, the states of the United States of America and the District of Columbia) ("United States") or any other jurisdiction. This publication may not be distributed, published or circulated in the United States, Australia, Canada, Japan and other countries where such distribution or publication may be unlawful.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act, or in a transaction not subject to the registration requirements of the Securities Act. or the applicable securities laws of Australia, Canada or Japan. There will be no public offering of shares of the Company.

The distribution of this announcement may be restricted by law in certain jurisdictions and persons in possession this announcement or the information referred to herein should inform themselves about and observe any such restrictions. Failure to comply with such restrictions may constitute a violation of the securities laws of such jurisdictions.

About Formycon:

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. Formycon AG is listed in the Open Market ("Scale") of the Frankfurt Stock Exchange (ISIN: DE000A1EWVY8 / WKN: A1EWVY).

About Biosimilars:

Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2025, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Currently, global sales of biosimilars are estimated at more than USD 15 billion. By 2030, analysts estimate that this figure could rise to over USD 74 billion.

Contact:
Sabrina Müller
Director Investor Relations and Corporate Communications

Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany

phone +49 (0) 89 - 86 46 67 149
fax + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com